- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01509612
Additive Homeopathy in Cancer Patients (HIC)
Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter Study Evaluating Quality of Life in Patients With Advanced Malignant Lung Tumors With or Without "add-on" Homeopathy
The investigators aim to investigate the validity of their previous results in a randomized prospective, placebo-controlled, double-blind, multicenter controlled evaluation of questionnaires in patients with advanced malignant tumors. The investigators plan to compare the treatment outcome (quality of life and survival) in tumor patients, receiving standard or "add-on" homeopathic treatment.
The null hypothesis is that "add-on" homeopathic treatment does not create a benefit for cancer patients. In addition the investigators evaluate survival time.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Wien, Austria, 1120
- Michael Frass
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed consent
- Clinical diagnosis of advanced tumor stages of non small-cell lung carcinoma (NSCLC) IIIB, IIIC, IV.
Exclusion Criteria:
- sensitizing mutation of the EGFR gene or translocation of the ALK gene
- refusal to sign informed consent
- pregnancy
- hematological, hepatic, or renal pathology
- coronary heart disease
- history of secondary tumor
- major surgery within 4 weeks prior to study entry
- active infection and symptomatic peripheral neuropathy
- central nervous system metastases unless the metastases were treated and stable
- active autoimmune disease
- use of systemic immunosuppressive treatment
- use of systemic treatment during the previous 2 years
- active interstitial lung disease, or a history of pneumonitis for which glucocorticoids were prescribed
- previous systemic therapy for metastatic disease or previous irradiation
- use of any complementary and/or alternative therapy, including homeopathy other than the research treatment during the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Additive homeopathy in cancer patients
Lung cancer patients receiving conventional chemo- and/or radiation therapy receive additive classical homeopathy with homeopathic globules
|
Homeopathic remedies every 2 to 3 months
Other Names:
|
PLACEBO_COMPARATOR: Additive homeopathic placebo globules
Lung cancer patients receiving conventional chemo- and/or radiation therapy receive homeopathic placebo globules
|
Homeopathic placebo globules every 2 to 3 months
Other Names:
|
NO_INTERVENTION: No intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
EORTC-QLQ-C30 Score
Time Frame: baseline and at 18 weeks
|
Quality of life was evaluated by using the Global Health Status assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30), which was completed by participants throughout the study. The score of the scale ranges from 0-100, where high values mean good health status, while lower values indicate poor health status. |
baseline and at 18 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival
Time Frame: 2 years for the individual patient (=whole study duration)
|
Survival was assessed by chart review, at every study visit (every 9 weeks throughout the trial), and by information of the central mortality registry of Austria
|
2 years for the individual patient (=whole study duration)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael Frass, Prof. Dr., Medical University Vienna
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Tumors
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedMalignant Tumors | Refractory TumorsFrance
-
Peking Union Medical College HospitalPeking University; Peking University Cancer Hospital & InstituteRecruiting
-
Bristol-Myers SquibbOno Pharmaceutical Co. LtdCompletedMalignant TumorsJapan
-
InnoPharmax Inc.CompletedMalignant TumorsTaiwan, United States
-
Nanjing Leads Biolabs Co.,LtdRecruiting
-
Memorial Sloan Kettering Cancer CenterRecruitingMalignant Solid TumorsUnited States
-
LaNova Medicines LimitedSuspendedMalignant TumorsChina
-
SUNHO(China)BioPharmaceutical CO., Ltd.RecruitingAdvanced Malignant TumorsChina
-
Fudan UniversityRecruitingAdvanced Malignant TumorsChina
-
AkesoRecruitingAdvanced Malignant TumorsChina
Clinical Trials on Additive classical homeopathy
-
Innowage LimitedGyansanjeevani India; Collaborative Homeopathy Research NetworkCompletedPost-COVID SyndromeIndia
-
Monell Chemical Senses CenterHVMN (funding; holder of primary Department of Defense STTR contract)CompletedFlavor Perception in Normal, Healthy AdultsUnited States
-
Adwin Life CareCenter For Homeopathy Research, India; Sonal Foundation, IndiaCompletedCancer | Chronic InsomniaIndia
-
Shaare Zedek Medical CenterCompleted
-
Sheba Medical CenterTechnion, Israel Institute of TechnologyCompleted
-
Shaare Zedek Medical CenterHadassah Medical OrganizationUnknown
-
Ankara Yildirim Beyazıt UniversityNot yet recruiting
-
Swiss Paraplegic Research, NottwilCompletedSpinal Cord Injury | Symptomatic Urinary Tract InfectionSwitzerland
-
Mansoura UniversityCompleted
-
Shaare Zedek Medical CenterUnknownPatients Undergoing Open Heart Surgery | Patients Undergoing Lung SurgeryIsrael